君实生物(01877.HK)：抗IL-17A单抗治疗中重度斑块状银屑病的Ⅲ期临床研究达到主要研究终点

Core Viewpoint - Junshi Biosciences (01877.HK) announced positive results from a pivotal Phase III clinical trial of its product, JS005, a humanized anti-IL-17A monoclonal antibody, for the treatment of moderate to severe plaque psoriasis, demonstrating statistical significance and clinical relevance in both primary and key secondary endpoints [1] Group 1 - The clinical trial was a multicenter, randomized, double-blind, parallel, placebo-controlled study [1] - The study identifier for the trial is JS005-005-III-PsO [1] - Both primary and key secondary endpoints showed statistically significant and clinically meaningful improvements [1]